Immupharma (IMM)

 

IMM Share PerformanceMore

52 week high53.00 11/01/17
52 week low22.75 10/02/16
52 week change 25.13 (94.81%)
4 week volume2,730,359 21/12/16

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Holding(s) in Company

RNS Number: 9563S Immupharma PLC 29 December 2016 RNS: FOR IMMEDIATE RELEASE 29 DECEMBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") TR1 NOTIFICATION OF MAJOR INTEREST ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Ca...

ImmuPharma completes Lupuzor patient recruitment

ImmuPharma has confirmed that patient recruitment has successfully been completed, on target, within the company's pi...

Update on Lupuzor Pivotal Phase III Study

RNS Number: 5353S Immupharma PLC 22 December 2016 RNS: FOR IMMEDIATE RELEASE 22 DECEMBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") Update on Lupuzor Pivotal Phase III Study Patient Recruitment Completed ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, is pleased to confirm tha...

ImmuPharma update on cancer compound

ImmuPharma has announced that Cancer Research, the prestigious medical journal of the American Association for Can...

Update on Cancer Compound IPP-204106 'Nucant'

RNS Number: 2696P Immupharma PLC 16 November 2016 RNS REACH: FOR IMMEDIATE RELEASE 16 NOVEMBER 2016 IMMUPHARMA PLC Update on Cancer Compound IPP-204106 'Nucant' Mechanism of Action Published in Prestigious Medical Journal 'Cancer Research' ImmuPharma plc (LSE:IMM) ("ImmuPharma" or the "Company" or the "Group")...

Holding(s) in Company

RNS Number: 6800O Immupharma PLC 09 November 2016 RNS: FOR IMMEDIATE RELEASE 9 NOVEMBER 2016 NOTIFICATION OF MAJOR INTEREST BY LEGAL & GENERAL ImmuPharma PLC (LSE:IMM) ("ImmuPharma" or the "Company"), the specialist drug discovery and development company, announces that it has received notification by Leg...

Holding(s) in Company

RNS Number: 5484N Immupharma PLC 26 October 2016 RNS: FOR IMMEDIATE RELEASE 26 OCTOBER 2016 ImmuPharma PLC ("ImmuPharma" or the "Company") TR1 NOTIFICATION OF MAJOR INTEREST ImmuPharma PLC (LSE:IMM) , the specialist drug discovery and development company, announces that it has received a TR-1 by Lanstead Capita...

ImmuPharma fundraising

ImmuPharma has placed 7,100,000 existing ordinary shares and raised a total of 1 million, gross, through the issue of 2,857,1...

Fundamental DataMore

EPS-4.4
Dividend yield0 %

Latest discussion posts More

  • Lupuzor update

    "ImmuPharma has announced that it has been invited to open an additional site in Mauritius as part of its Phase III clinical trial of Lupuzor?, its lead programme for the ...
    7-Sep-2016
    Sambram
  • Re: SP ACTION

    Tail wagging the dog again!
    11-Aug-2016
    rpg7
  • Re: Lupuzor trial steps up

    Two notes out this morning (both on research tree): Panmure: "Last week, ImmuPharma hosted a symposium featuring Prof Sylviane Muller, the inventor of Lupuzor, detailing ...
    14-Jun-2016
    Simbr

Users' HoldingsMore

Users who hold Immupharma also hold..
LLOYDS GRP.27%
BP18%
ROYAL BANK SCOT13%
GLAXOSMITHKLINE12%
NATIONAL GRID12%

Codes & Symbols

ISINGB0033711010
SymbolsIMM, LSE:IMM, IMM.L, IMM:LN, LON:IMM, XLON:IMM